The thyroid cancer he had battled for 14 years was back and spreading.
Then, earlier this year, he began taking lenvatinib, a drug that was tested at MD Anderson and approved by the Food and Drug Administration (FDA) in February. Lenvatinib treats patients such as Pantoja, whose thyroid cancer doesn’t respond to the more traditional radioactive iodine therapy. It uses targeted radiation to destroy any thyroid tissue or cancer cells that remain after the thyroid is surgically removed.
For decades, the standard treatment was to administer repeated and often ineffective doses of radioactive iodine, and sometimes chemotherapy,” says Steven Sherman, M.D., associate vice provost for Clinical Research. “About 10 years ago, with new scientific discoveries, we began recognizing the potential for treating patients with drugs that stop tumors from growing their own blood vessels.”
That’s exactly how lenvatinib works. A global study of the drug, also known as Lenvima, demonstrated a dramatic improvement in progression-free survival, with a 65% response rate.
“These are unprecedented results for thyroid cancer patients with such advanced disease,” says Sherman, who led the study.
Pantoja, who has been under the care of Steven Waguespack, M.D., professor of Endocrine Neoplasia and Hormonal Disorders (pictured above), directly benefited as a result of the clinical trials. So far, he hasn’t experienced many of the side effects that sometimes accompany the drug, including diarrhea, fatigue, nausea and weight loss. He is, however, among the 40% of patients whose blood pressure rises after taking Lenvima. He’s now on medication to keep his blood pressure in check.
“Lenvima appears to be working,” says Pantoja, who underwent several surgeries to remove sections of his arm bone after the cancer spread. “I’m already seeing a 75% reduction in thyroglobulin.”
The decline in thyroglobulin — a protein produced by both normal and cancerous thyroid tissue — is usually good news for patients being treated for advanced thyroid cancer.